Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipients;Utilidad de la amfotericina B liposomal para la prevención de la infección fúngica en receptores de un trasplante de órgano sólido

Revista Espanola de Quimioterapia

Volumn 18, Issue 1, 2005, Pages 14-20

  López Medrano, Francisco ^a   Diaz Pedroche C ^a   Lumbreras, C ^a   Aguado, J M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Fungal infections; Liposomal amphotericin B; Prophylaxis; Solid organ transplantation

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; META ANALYSIS; MYCOSIS; NEBULIZER; NEPHROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; REVIEW; SYSTEMATIC REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; HUMANS; LIPOSOMES; MYCOSES; ORGAN TRANSPLANTATION;

EID: 18844395592     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Gavaldá, J., Pahissa, A. Factores de riesgo y cronología de la infection en el trasplante de órgano sólido. Enferm Infecc Microbiol Clin 1997; 15 (Suppl. 2): 3-11.
2. Lumbreras, C., Otero, J.R., Aguado, J.M. Prevención de la infección en receptores de trasplante de órgano sólido. Enferm Infecc Microbiol Clin 1997; 15 (Suppl. 2): 77-89.
3. Muñoz, P., Bouza, E. Prevención y tratamiento de las infecciones fúngicas en receptores de trasplante de órgano sólido. Rev Clin Esp 1995; 195: 38-47.
4. Paya, C.V. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677-688.
5. Muñoz, P., Bouza, E. Infecciones por hongos en el paciente sometido a trasplante de órgano sólido. Enferm Infecc Microbiol Clin 1997; 15 (Suppl. 2): 34-50.
6. Wong-Beringer, A., Jacobs, R.A., Guglielmo, B.J. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-618.
7. Prentice, H.G., Hann, I.M., Herbrecht, R. y cols. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
8. Walsh, T.J., Finberg, R.W., Arndt, C. y cols. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
9. Ascioglu, S., Rex, J.H., de Pauw, B. y cols. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
10. Leenders, A.C., Daenen, S., Jansen, R.L. y cols. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-212.
11. Barrett, J., Vardulaki, K.A., Conlon, C. y cols. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295-1320.
12. Johansen, H.K., Gotzsche, P.C. Amphotericin B lipid formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2000; CD000969.
13. Dupont, B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49 (Suppl. 1): 31-36.
14. Dismukes, W.E. Introduction to antifungal drugs. Clin Infect Dis 2000; 30: 653-657.
15. Ostrosky-Zeichner, L., Marr, K.A., Rex, J.H., Cohen, S.H. Amphotericin B: Time for a new "gold standard". Clin Infect Dis 2003; 37: 415-425.
16. Wingard, J.R., White, M.H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-1163.
17. Cagnoni, P.J., Walsh, T.J., Prendergast, M.M. y cols. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18: 2476-2483.
18. Gavaldá, J., Pahissa, A. Visión actual de la infección fúngica en elpaciente sometido a un trasplante de órgano sölido. Enferm Infecc Microbiol Clin (Monogr.) 2002; 1: 21-31.
19. Tollemar, J. Prophylaxis against fungal infections in transplant recipients: Possible approaches. BioDrugs 1999; 11: 309-318.
20. Boswell, G.W., Buell, D., Bekersky, I. AmBisome (liposomal amphotericin B): A comparative review. J Clin Pharmacol 1998; 38: 583-592.
21. Adler-Moore, J., Proffitt, R.T. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 (Suppl. 1): 21-30.
22. Tollemar, J., Hockerstedt, K., Ericzon, B.G., Jalanko, H., Ringden, O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995; 59: 45-50.
23. Lorf, T., Braun, F., Ruchel, R., Muller, A., Sattler, B., Ringe, B. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 1999; 42: 47-53.
24. Singh, N., Paterson, D.L., Gayowski, T., Wagener, M.M., Marino, I.R. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71: 910-913.
25. Varo, E., Tomé, S., Bustamante, M. y cols. Fungal infection prophylaxis in high-risk liver transplant recipients. En: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998; Abstr. J138.
26. Fortún, J., Martín-Davila, P., Moreno, S., Barcena, R., de Vicente, E., Honrubia, A. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813-819.
27. Fortún, J., Martín-Davila, P., Moreno, S. y cols. Risks factors for invasive aspergillosis in liver transplant recipients. Liver Transplant 2002; 8: 1065-1070.
28. Briegel, J., Forst, H., Spill, B. y cols. Risks factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microb Infect Dis 1995; 14: 375-382.
29. Drew, R.H., Dodds Ashley, E., Benjamin, D.K., Jr., Duane Davis, R., Palmer, S.M., Perfect, J.R. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232-237.
30. Gavaldá, J., López, P., Martín, M.T., Gomis, X., Ramírez, J.L., Pahissa, A. Eficacia de la amfotericina B liposomal nebulizada en el tratamiento de la aspergilosis pulmonar experimental. Enferm Infecc Microbiol Clin 2004; 22 (Suppl. 1): 126.
31. López Medrano, F., Lumbreras, C., Otero, J.R. y cols. Eficacia del tratamiento anticipado con ganciclovir en la prevención de la enfermedad par citomegalovirus en receptores de un trasplante de hígado. Med Clin (Barc) 2004; 122: 41-45.
32. Mennink-Kersten, M.A., Donnelly, J.P., Verweij, P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357.
33. Paya, C.V. Prevention of fungal infection in transplantation. Transpl Infect Dis 2002; 4 (Suppl. 3): 46-51.